New coronavirus vaccine expected to be clinically tested in humans in 3 months

U.S. health officials and researchers in the Journal of the American Medical Association published a comment article on the 23rd, said that since the emergence of severe acute respiratory syndrome (SARS), the medical community’s research and technological advances in the coronavirus can greatly shorten the development of new coronavirus vaccine time. A candidate vaccine for the new coronavirus is expected to begin human clinical trials in three months.

New coronavirus vaccine expected to be clinically tested in humans in 3 months

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, and Kathleen Paules, an infectious disease expert at the University of Pennsylvania School of Medicine, wrote that it took 20 months to obtain the genome sequence of sars coronavirus to the Phase I clinical trial for the first vaccine. However, the subsequent study of SARS coronavirus and Middle East Respiratory Syndrome (MERS) coronavirus provides an important basis for decoding and responding to new coronaviruses.

The paper points out that the protogloa on the surface of SARS coronavirus treats human angiotensin-conversion enzyme 2 as the main receptor for invasion. Preliminary analysis shows that the new coronavirus and SARS coronavirus have a certain degree of amino acid homologous, may also be human angiotensin conversion enzyme 2 as a receptor.

Baylor College of Medicine is currently working with the University of Texas, the New York Blood Center and Fudan University in China to develop vaccines. The U.S. National Institutes of Health is also working on a vaccine against the new coronavirus. The current average time for the development of viral vaccines is about 3.25 months, and with the help of messenger RNA (mRNA) vaccine technology, the development of new coronavirus vaccines is expected to be more rapid.

Experts also believe that the broad-spectrum antiviral drug Remdesivir, the antiretroviral drug Lopinavir/Litonavir and beta interferon have shown some efficacy in animal experiments with MERS, and researchers are currently evaluating whether they can be used to treat the new coronavirus.